Synaptogenix Files Definitive Proxy Statement

TL;DR

Synaptogenix (formerly Neurotrope) filed its proxy statement - shareholders vote soon.

AI Summary

Synaptogenix, Inc. filed a Definitive Proxy Statement (DEFA14A) on November 20, 2024. The filing concerns matters to be voted on by shareholders, as indicated by the proxy statement format. The company, formerly known as Neurotrope Bioscience, Inc., is incorporated in Delaware and headquartered in New York.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda and proposals for the upcoming shareholder meeting, allowing them to make informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently present new risks to the company or its investors.

Key Players & Entities

• Synaptogenix, Inc. (company) — Registrant
• Neurotrope Bioscience, Inc. (company) — Former company name
• 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036 (location) — Business and Mail Address
• 20241120 (date) — Filing Date

FAQ

Filing Documents

• tm2428927d1_defa14a.htm (DEFA14A) — 26KB
• tm2428927d1_defa14a001.jpg (GRAPHIC) — 174KB
• tm2428927d1_defa14a002.jpg (GRAPHIC) — 202KB
• 0001104659-24-120714.txt ( ) — 545KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Under §240.14a-12 Synaptogenix, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 SYNAPTOGENIX, INC. 1185 Avenue of the Americas, 3rd Floor, New York, New York 10036 SUPPLEMENT NO. 1 TO THE PROXY STATEMENT FOR THE SYNAPTOGENIX, INC . ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 6, 2024 This Supplement No. 1 (this “Supplement”), dated November 19, 2024, supplements the definiti ve proxy statement on Schedule 14A (the “Proxy Statement”) filed by Synaptogenix, Inc., a Delaware corporation (referred to herein as “we”, “us”, “our” or the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”) on November 7, 2024, in connection with the solicitation by the Company’s Board of Directors (the “Board”) of proxies to be voted at the Company’s 2024 Annual Meeting of Stockholders, or any adjournment or postponement thereof (the “Annual Meeting”). TH IS SUPPLEMENT SHOULD BE READ IN CONJUNCTION WITH THE PROXY STATEMENT, WHICH CONTAINS IMPORTANT ADDITIONAL INFORMATION. Except as to the matters specifically discussed herein, this Supplement does not otherwise modify or update any information or disclosure contained in the Proxy *** To Our Stockholders: You recently received a copy of the proxy statement relating to the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Synaptogenix, Inc. (the “Company”). After the proxy statement was mailed, we discovered that the proxy card enclosed therewith incorrectly stated that “Alan Tuchman, M.D.” and “Daniel L. Alkon, M.D.” are director nominees for election pursuant to Proposal no. 1. As disclosed in the proxy statement, the Board nominated Joshua N. Silverman and William S. Singer for election at the Annual Meeting. A corrected proxy card is enclosed herewith . The date of the Annual Meeting remains Friday, December 6, 2024. No revisions are being made to the previous proxy statement, as filed with the Securities and Exchange Commission on November 7, 2024. In light of the error described above, this Supplement includes a new proxy card that corrects the director nominees for election pursuant to Proposal no. 1. Any vote cast in favor of either Alan Tuchman, M.D. or Daniel L. Alkon, M.D. on the previously distributed proxy card will not be recognized, tabulated at the Annual Meeting or have any legal effect. Stockholders who submitted the previously distributed proxy card voting “FOR” either Alan Tuchman, M.D. or Daniel L. Alkon, M.D. can revoke that proxy by completing, signing, dating and promptly returning the new proxy card in the postage-paid envelope provided or by voting via the Internet or telephone by following the instructions on the new proxy card.. As stated in the proxy statement you received previously, you may revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways: · if you received a proxy card, by signing a new proxy card with a date later than your previously delivered proxy and submitting it as instructed; · by re-voting by Internet or by telephone as instructed above; · by notifying Synaptogenix’s Secretary in writing before the Annual Meeting that you have revoked your proxy; or · by attending the Annual Meeting and voting at the meeting. Attending the Annual Meeting will not in and of itself revoke a previously submitted proxy. You must specifically request at the Annual Meeting that it be revoked. If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank if you wish to revoke your proxy. The enclosed amended proxy card, along with the current version of the proxy materials for the Annual Meeting and our Annual Report on Form 10-K for the year ended December 31, 2023, are also available at https://web.viewproxy.com/synaptogenixinc/2024 Please accept our apology for any confusion this printing error may

View Full Filing

View this DEFA14A filing on SEC EDGAR